Phase 2 Osteoporosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 50 or older, or men aged 70 or older
- People who have been in the Intensive Care Unit (ICU) for at least 2 full days and are not expected to leave the ICU on that second day
- People who have needed a significant level of ICU support — such as breathing machines, oxygen therapy at high levels, or medications to support blood pressure — for at least 6 hours in total
- People who are expected to survive their current hospital stay
Who may not be able to join:
- People who have cancer that has spread to the bones, or who have a blood cancer called multiple myeloma
- People who have a bone condition called Paget's disease
- People who are pregnant
- People whose kidneys are not working well enough (based on a specific blood test result), or who are already receiving dialysis or a similar kidney treatment
- People who are known to have a reason they cannot take either of the study medications (denosumab or zoledronic acid)
- People who have obvious holes in their teeth, broken teeth, or a current dental or gum infection
- People with a known, untreated condition where the parathyroid glands do not work properly (confirm with trial site)
- People currently being treated with certain bone-strengthening medications — including bisphosphonates, strontium, or teriparatide within the past 2 years, or hormone therapy or romosozumab within the past 12 months, or denosumab within the past 6 months
- People who currently have a fragility fracture (a break caused by weakened bones) of the hip, spine, thigh bone, or forearm
- People whose body weight exceeds the limit for the bone density scanning equipment at the trial site, or who are unable to have a bone density scan for any reason
- People with certain abnormal blood test results related to blood clotting or platelet levels
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neil Orford, A/Prof, Barwon Health; ANZIC Research Centre
Phone: +61 3 9903 0343
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
20 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualised change in femoral neck bone mineral density for the year after Intensive Care discharge
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.